SABCS 2018: Phase III KATHERINE clinical trial crossed early reporting boundary and met its primary endpoint
Substituting trastuzumab emtansine (T-DM1, Kadcyla) for adjuvant trastuzumab (Herceptin) in patients who had residual disease…
Browsing: KATHERINE trial